<DOC>
	<DOCNO>NCT02142010</DOCNO>
	<brief_summary>The purpose study evaluate pathological complete response ( pCR ) rate breast cancer patient treat weekly paclitaxel liposome injection plus cisplatin preoperative regimen .</brief_summary>
	<brief_title>Weekly Paclitaxel Liposome Injection Plus Cisplatin Preoperative Treatment Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Women age ≥ 18 year &lt; 65 year , An estimated life expectancy least 12 month ECOG 01 At least one measurable disease accord RECIST . histologically confirm invasive breast cancer , stage II III , prior systemic locoregional treatment breast cancer Biopsy specimens available ER , PgR Her2 analysis Adequate bone marrow function : Neutrophil ≥ 1.5*109/L ; Hb ≥ 100g/L ; PLT ≥ 100*109/L adequate liver function ( bilirubin &gt; 1.0 time upper normal limit [ UNL ] ALT and/or AST &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL ; Women potential childbearing must negative pregnancy test ( urine serum ) within 7 day drug administration agree use acceptable method birth control avoid pregnancy duration study No obvious main organ dysfunction patient must accessible treatment followup write informed consent Patient pregnant breast feed Inflammatory breast cancer Metastatic breast cancer Patients medical condition indicate intolerant neoadjuvant therapy relate treatment , include uncontrolled pulmonary disease , diabetes mellitis , severe infection , active peptic ulcer , coagulation disorder , connective tissue disease myelosuppressive disease History congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) Has peripheral neuropathy Treatment investigational drug within 30 day begin study treatment No psychiatric illness situation would limit compliance study With history malignant tumor Known severe hypersensitivity drug study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>